Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis hepatitis B treatment beats GSK drug in trial
The ongoing phase III trial is evaluating the drug in the treatment of 332 Chinese patients. According to Idenix, mainland China has the largest population affected by the
The ongoing phase III trial is evaluating the drug in the treatment of 332 Chinese patients. According to Idenix, mainland China has the largest population affected by the
Currently marketed in Japan, Glufast is an insulin secretagogue that lowers post-meal glucose levels by improving the body’s own ability to produce insulin. Glufast has undergone extensive clinical
The acquisition is a strategic move by Sanofi-Aventis designed to develop its business in Central and Eastern Europe. Zentiva, which achieved sales in 2005 of E410 million, has
In a license agreement with the University’s technology transfer company, Isis Innovation, Geron receives a worldwide exclusive license for pioneering work by Oxford scientists who derived dendritic cells
The agreement with Inex Pharmaceuticals provides access to fundamental liposome delivery technology for systemic RNAi therapeutics. The agreement with the Massachusetts Institute of Technology (MIT) provides access to
The company has already won approval for a capsule form of the drug and Gerald Proehl, president and CEO of Santarus, explained that the company would not immediately
The vaccine combines antigens for protection against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and hemophilus influenza type b, one of the leading causes
Alnylam and its collaborators at Protiva Biotherapeutics, demonstrated silencing in primates of the gene for apolipoprotein B (apoB), a protein involved in cholesterol metabolism, with clinically significant efficacy
The letter contains concerns and observations that must be satisfied prior to achieving approval, including a request for additional clinical trial work. If the company does need to
Cubicin is already approved for the treatment of complicated skin infections, but the company is now seeking approval for the drug as a treatment for S aureus bacteremia,